𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Feasibility of a dose-adjusted fludarabine–melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma

✍ Scribed by Andrea Tendas; Luca Cupelli; Teresa Dentamaro; Laura Scaramucci; Roberto Palumbo; Pasquale Niscola; Marco Giovannini; Daniela Piccioni; Alessio Pio Perrotti; Paolo de Fabritiis

Publisher
Springer
Year
2008
Tongue
English
Weight
57 KB
Volume
88
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The feasibility of neoadjuvant high-dose
The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma : Results of a phase II study
✍ Fikret Arpaci; Selmin Ataergin; Ahmet Ozet; Kaan Erler; Mustafa Basbozkurt; Ayha 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract ## BACKGROUND The primary and secondary objectives of the current study were to improve the ≥ 90% tumor necrosis rate and assess the toxicity profile of the neoadjuvant high‐dose chemotherapy (HDC) regimen, respectively. ## METHODS Twenty‐two patients with AJCC Stage IIB high‐grade o

Cyclophosphamide plus dexamethasone is a
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame